19 studies found for:    Progressive Multifocal Leukoencephalopathy
Show Display Options
Rank Status Study
1 Recruiting Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Condition: Progressive Multifocal Leukoencephalopathy
Intervention:
2 Completed A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
Conditions: HIV Infections;   Leukoencephalopathy, Progressive Multifocal
Interventions: Drug: Interferon alfa-2b;   Drug: Zidovudine
3 Completed Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
Conditions: HIV Infections;   Leukoencephalopathy, Progressive Multifocal
Interventions: Drug: Filgrastim;   Drug: Cytarabine;   Drug: Zidovudine;   Drug: Zalcitabine;   Drug: Didanosine
4 Recruiting Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Conditions: Progressive Multifocal Leukoencephalopathy;   Immune Reconstitution Syndrome;   Acquired Immunodeficiency Syndrome;   Multiple Sclerosis
Intervention:
5 Completed Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
Conditions: Leukoencephalopathy, Progressive Multifocal;   HIV Infections
Interventions: Drug: Enfuvirtide;   Drug: Tenofovir-Emtricitabine
6 Completed Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)
Conditions: HIV Infections;   Leukoencephalopathy, Progressive Multifocal
Intervention: Drug: Topotecan
7 Completed A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
Conditions: HIV Infections;   Leukoencephalopathy, Progressive Multifocal
Interventions: Drug: Cidofovir;   Drug: Probenecid
8 Terminated Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)
Condition: Progressive Multifocal Leukoencephalopathy
Intervention: Drug: mefloquine
9 Enrolling by invitation Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
Condition: Progressive Multifocal Leukoencephalopathy
Intervention:
10 Completed Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
Conditions: Immune Reconstitution Inflammatory Syndrome;   Leukoencephalopathy, Progressive Multifocal
Intervention: Drug: corticosteroids
11 Completed Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome
Conditions: PML;   AIDS
Intervention:
12 Active, not recruiting (1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
Conditions: Cancer;   Central Nervous System Disease;   Nervous System Disease;   Peripheral Nervous System Disease;   Progressive Multifocal Leukoencephalopathy
Intervention:
13 Completed A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
Conditions: HIV Infections;   Leukoencephalopathy, Progressive Multifocal
Intervention: Drug: Didanosine
14 Recruiting Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1b
15 Completed Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Drug: vedolizumab (MLN0002)
16 Recruiting Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Condition: Kidney Transplantation
Intervention: Drug: No Intervention
17 Completed Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort
Conditions: Multiple Sclerosis;   Relapse
Intervention:
18 Recruiting Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control
Condition: Multiple Sclerosis
Intervention:
19 Active, not recruiting Drug Exposure Registry for GSK2248761, an Investigational NNRTI
Conditions: Seizures;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK2248761

Indicates status has not been verified in more than two years